Subtype
Urinary Tract Neoplasm
CI-CAN-00001627Explore in graph →
Non-malignant558 active trials14 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001627Explore in graph →
Clinical trials
2,187 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05614739 | FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3(FORAGER-1) | recruiting | Phase 1 | 677 | Eli Lilly and CompanyINDUSTRY | 14 | Aug 20, 2026 | clinicaltrials |
| NCT07129993 | Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 2 / Phase 3 | 630 | Daiichi SankyoINDUSTRY | 7 |
| Aug 20, 2026 |
| clinicaltrials |
| NCT07227077 | Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial | recruiting | N/A | 50 | Medical College of WisconsinOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03193970 | Measuring Surgical Recovery After Radical Cystectomy | recruiting | — | 2,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02609269 | Decipher Genomics Resource for Intelligent Discovery(GRID®) | enrolling by invitation | — | 1,000,000 | GenomeDx Biosciences CorpINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT06966024 | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | recruiting | Phase 1 | 60 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07097142 | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study | recruiting | Phase 3 | 486 | NRG OncologyOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT05776758 | Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt | active not recruiting | Phase 3 | 236 | Regina Elena Cancer InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06011954 | A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection | recruiting | — | 202 | Astellas Pharma Korea, Inc.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07762820 | REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors(RETRIEVE-BT) | not yet recruiting | N/A | 75 | Ludwig-Maximilians - University of MunichOTHER | 3 | Aug 17, 2026 | clinicaltrials |
| NCT05335941 | A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma | active not recruiting | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07187635 | Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer | recruiting | N/A | 196 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07726602 | Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial | recruiting | — | 100 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07758881 | Evaluating the Safety and Performance of the Eight Medical Hyperthermia System IV 1.0 for HIVEC in NMIBC. | not yet recruiting | N/A | 30 | Eight Medical International BVINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06041503 | Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) | recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07762586 | Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC) | recruiting | Phase 2 | 60 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07763197 | Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)(SCORE-NMIBC) | recruiting | — | 400 | Natera, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05929235 | A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma | active not recruiting | Phase 1 | 120 | Flare Therapeutics Inc.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04164082 | Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer | active not recruiting | Phase 2 | 161 | National Cancer Institute (NCI)NIH | 3 | Aug 11, 2026 | clinicaltrials |
| NCT04179162 | Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment | active not recruiting | Phase 1 / Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT06891209 | Exploration of HRQOL and Urinary Outcomes Following Partial Cystectomy | recruiting | — | 300 | Mayo ClinicOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04923178 | A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies | recruiting | — | 1,100 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07756008 | Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer | not yet recruiting | Phase 2 / Phase 3 | 114 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07756437 | Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer(BLUT-DNA) | recruiting | — | 70 | AZ Sint-Lucas GentOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04752722 | LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | recruiting | Phase 1 / Phase 2 | 350 | enGene, Inc.INDUSTRY | 10 | Aug 7, 2026 | clinicaltrials |
| NCT05137262 | A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder | active not recruiting | Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07751796 | OptiCross HD IVUS for Assessing Invasion Depth in Upper Tract Urothelial Carcinoma | not yet recruiting | N/A | 15 | Yonsei UniversityOTHER | 0 | Aug 7, 2026 | clinicaltrials |
| NCT01050504 | Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer | recruiting | — | 1,500 | University of WashingtonOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05055050 | A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630 | active not recruiting | Phase 1 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05483868 | A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer | active not recruiting | Phase 1 | 55 | Aura BiosciencesINDUSTRY | 2 | Aug 6, 2026 | clinicaltrials |
| NCT05581004 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 165 | Genentech, Inc.INDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT05868265 | A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract | active not recruiting | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06417190 | Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology | recruiting | Phase 2 | 20 | Leslie BallasOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749924 | Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC | not yet recruiting | N/A | 670 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03459846 | A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)(BAYOU) | active not recruiting | Phase 2 | 154 | AstraZenecaINDUSTRY | 7 | Aug 5, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06809140 | Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer | recruiting | Phase 2 | 75 | Matthew GalskyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07000084 | Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy(GAIN-BCG) | recruiting | Phase 3 | 330 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT06960577 | Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) | recruiting | Phase 3 | 150 | AstraZenecaINDUSTRY | 7 | Aug 4, 2026 | clinicaltrials |
| NCT04934540 | The Global En Bloc Resection of Bladder Tumour Registry | recruiting | — | 2,000 | Chinese University of Hong KongOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06124976 | Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma | recruiting | Phase 2 / Phase 3 | 70 | Peter BlackOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07724886 | Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC | not yet recruiting | N/A | 732 | Chinese University of Hong KongOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07741435 | Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia(METHYLSCAPE-CO) | recruiting | — | 3,250 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07741617 | A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma | not yet recruiting | Phase 2 | 54 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Aug 3, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 20, 2026source: clinicaltrials